乌司他丁抑制CCL17/CCL22-CCR4介导的小鼠乳腺癌肝转移

doi:10.19401/j.cnki.1007-3639.2018.04.002

中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (4): 248-255.doi: 10.19401/j.cnki.1007-3639.2018.04.002

乌司他丁抑制CCL17/CCL22-CCR4介导的小鼠乳腺癌肝转移

李霞，印国兵，程熙，潘倍倍，李顺波，代朦，郭丹

重庆医科大学附属第二医院乳腺甲状腺外科，重庆 400010

出版日期:2018-04-30 发布日期:2018-06-12
通信作者: 郭丹 E-mail：guodan-e1973814@126.com
基金资助:
重庆市科委社会事业与民生保障科技创新专项一般项目（cstc2016shmszx130012）。

Ulinastatin inhibits liver metastasis from breast cancer in mice through CCL17/CCL22–CCR4 pathway

LI Xia, YIN Guobing, CHENG Xi, PAN Beibei, LI Shunbo, DAI Meng, GUO Dan

Department of Breast and Thyroid Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

Published:2018-04-30 Online:2018-06-12
Contact: GUO Dan E-mail: guodan-e1973814@126.com

摘要/Abstract

摘要：

背景与目的：越来越多的研究表明趋化因子及其受体在癌症的发生、发展和转移中起关键作用。本文研究了乌司他丁（ulinastatin）对胸腺和活化调节趋化因子（thymus and activation-regulated chemokine，TARC）即CCL17/巨噬细胞来源的趋化因子（macrophage-derived chemokine，MDC）即CCL22-CC族趋化因子受体4（CC chemokine receptor 4，CCR4）信号通路介导的乳腺癌肝转移的影响及其作用机制。方法：通过小鼠乳腺脂肪垫（mfp）接种4T1乳腺癌细胞的方式构建小鼠乳腺癌模型，15 d后取小鼠乳腺肿瘤，并记录乳腺肿瘤的质量；采用免疫组织化学法检测乳腺肿瘤组织中CCR4及肝脏转移瘤中CCL22、CCL17蛋白的表达；采用慢病毒转染的方式抑制4T1乳腺癌细胞CCR4基因，采用蛋白质印迹法（Western blot）检测抑制效果，并以同样方式进行小鼠乳腺成瘤并观察肿瘤生长情况；用三种不同浓度乌司他丁处理4T1细胞荷瘤小鼠，15 d后采用免疫组织化学法检测乳腺癌组织中CCR4及肝脏组织中CCL22及CCL17的表达，采用Westernblot和实时荧光定量聚合酶链反应（real-time fluorescent quantitative polymerase chain reaction，RTFQ-PCR）分别检测肝脏组织中TGF-β的表达以及microRNA-34a和microRNA-31的含量，并进行TGF-β和microRNA-34a、microRNA-31、CCL22以及CCL17的相关性分析。结果：小鼠乳腺癌组织高表达CCR4，肝脏转移瘤高表达CCL22和CCL17；沉默4T1乳腺癌细胞CCR4的表达，可抑制乳腺癌成瘤性；乌司他丁抑制CCR4、TGF-β、CCL22、microRNA-31和CCL17的表达，促进microRNA-34a的表达。结论：乌司他丁具有抑制乳腺癌肝转移的作用，其具体机制可能与乌司他丁通过TGF-β-microRNA-34a-CCL22轴及microRNA-31-TGF-β-CCL17轴抑制肝乳腺癌；肝转移；乌司他丁；CCR4；CCL22；CCL17脏组织中与乳腺癌肝转移密切相关的CCL17/CCL22-CCR4信号通路有关。

关键词: 乳腺癌, 肝转移, 乌司他丁, CCR4, CCL22, CCL17

Abstract: Background and purpose: Increasing evidences have shown the key roles of chemokines in the formation and metastasis of cancers. In this study, we investigated the molecular mechanisms of liver metastasis from breast cancer and the effects of ulinastatin on liver metastasis from breast cancer mediated by CCL17/CCL22–CCR4 pathway. Methods: A mouse xenograft model and corresponding control were established by subcutaneously inoculating 4T1 breast cancer cells into mouse mammary fat pad. Fifteen days later, the mice were sacrificed, and the breast tumors were weighed. Immunohistochemistry was performed to detect CCR4 protein expression in breast tumors and CCL22 and CCL17 protein expressions in liver metastasis. The CCR4 gene was found to be inhibited by lentiviral transduction in 4T1 breast cancer cells. Western blot was used to examine the inhibitory effect. The same method was used to induce breast tumorigenesis and to examine tumor growth. Three different concentrations of ulinastatin were used to treat 4T1 tumor-bearing mice. Fifteen days later, immunohistochemistry was used to assess the expression of CCR4 in breast tumors and the expression of CCL22 and CCL17 in liver tissues. Western blot and real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) were used to detect the expression of TGF-β, microRNA-34a and microRNA-31. We also analyzed the correlation between TGF-β and microRNA-34a, microRNA-31, CCL22, and CCL17. Results: Our results showed that CCR4 was highly expressed in mouse breast tumors. CCL22 and CCL17 were highly expressed in the liver metastasis. CCR4 expression was silenced in the 4T1 breast cancer cells and the in vivo growth of breast cancer xenograft tumor was inhibited. Ulinastatin significantly inhibited CCR4, TGF-β, CCL22, microRNA-31 and CCL17, but upregulated microRNA-34a. Conclusion: These results showed that ulinastatin can inhibit liver metastasis of breast cancer. The specific mechanism may involve ulinastatin acting on TGF-β-microRNA-34a-CCL22 and microRNA-31-TGF-β-CCL17 axes to inhibit CCL17/CCL22-CCR4 signaling pathway in liver tissues.

Key words: Breast cancer, Liver metastasis, Uinastatin, CCR4, CCL22, CCL17

李霞,印国兵,程熙,等. 乌司他丁抑制CCL17/CCL22-CCR4介导的小鼠乳腺癌肝转移[J]. 中国癌症杂志, 2018, 28(4): 248-255.

LI Xia, YIN Guobing, CHENG Xi, et al. Ulinastatin inhibits liver metastasis from breast cancer in mice through CCL17/CCL22–CCR4 pathway[J]. China Oncology, 2018, 28(4): 248-255.

[1]	章箎, 陈佳慧, 林瑾仪, 王妍, 张斯加, 朱玮, 程蕾蕾. 一种新型《乳腺癌治疗相关心血管毒性临床评分表》的价值分析[J]. 中国癌症杂志, 2022, 32(1): 54-60.
[2]	金奕滋, 林明曦, 张剑. DNA损伤应答缺陷作为乳腺癌治疗靶点的研究进展[J]. 中国癌症杂志, 2022, 32(1): 61-67.
[3]	《中国乳腺癌新辅助治疗专家共识（2022年版）》专家组. 中国乳腺癌新辅助治疗专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(1): 80-89.
[4]	张小艳, 李清祥, 刘　勇, 李　航, 仇丽娟, 封欣然, 谭立明 . HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究[J]. 中国癌症杂志, 2021, 31(9): 783-788.
[5]	曹爱玲, 曹　喆, 周　剑. 多西他赛联合胸腺肽α1对大鼠乳腺癌免疫微环境中Treg数量的影响及其机制研究[J]. 中国癌症杂志, 2021, 31(9): 799-806.
[6]	姚　嘉, 李冠乔, 杨时平, 苏慧銮 . Hsa-miR-98-5p/DKK3信号轴对乳腺癌细胞生物学行为的影响[J]. 中国癌症杂志, 2021, 31(9): 807-816.
[7]	丛斌斌, 王永胜. 激素受体阳性早期乳腺癌治疗现状与挑战[J]. 中国癌症杂志, 2021, 31(8): 689-696.
[8]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[9]	丁高峰, 郭雷鸣, 陆寓非. 乳腺癌患者HER2和BRCA1表达与放疗敏感性的关系研究[J]. 中国癌症杂志, 2021, 31(7): 589-595.
[10]	金优萍, 李录英, 周　平. 长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究[J]. 中国癌症杂志, 2021, 31(7): 596-604.
[11]	谢金芳, 曹春雨, 任　雪, 田家俊, 吕亚丰, 黄晓飞 . 萝卜硫素对小鼠乳腺癌4T1细胞上皮-间质转化、增殖和迁移的影响研究[J]. 中国癌症杂志, 2021, 31(7): 605-615.
[12]	曾　峰, 李　丹, 邵鑫鑫, 张能英, 陈星翰, 程晓明 . 基于SEER数据库构建1~2枚淋巴结阳性且乳房全切的老年早期乳腺癌患者不同腋窝手术方式的生存预测模型[J]. 中国癌症杂志, 2021, 31(4): 323-329.
[13]	王春建 , 聂　刚 , 毛　艳 . TRIP6在乳腺癌中的作用及其机制研究[J]. 中国癌症杂志, 2021, 31(3): 161-169.
[14]	胡喜娥, 杨振宇, 薛景毅, 杨　平, 彭书甲, 袁利娟, 包国强 . 单细胞测序在三阴性乳腺癌新辅助化疗中的应用研究进展[J]. 中国癌症杂志, 2021, 31(3): 221-226.
[15]	侯　净, 程纪淦, 王　华, 魏　娜, 倪　青. 硝呋齐特增加乳腺癌细胞对奥拉帕利敏感性的初步研究[J]. 中国癌症杂志, 2021, 31(12): 1168-1173.

乌司他丁抑制CCL17/CCL22-CCR4介导的小鼠乳腺癌肝转移

Ulinastatin inhibits liver metastasis from breast cancer in mice through CCL17/CCL22–CCR4 pathway

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价